Mexico Antacids Market Overview, 2031

Key Insights

• According to the research report, " Mexico Antacids Market Outlook, 2031," published by Bonafide Research, the Mexico Antacids Market is anticipated to grow at more than 4.69% CAGR from 2026 to 2031.
• Gastrointestinal disorders represent a major public health concern in Mexico. Population-based epidemiological studies indicate that 19.6% of adults in Mexico experience uninvestigated heartburn, while Functional Gastrointestinal Disorders (FGIDs) account for high rates of healthcare utilization across the country. Dietary habits specifically high consumption of spicy foods, fried cuisine, citrus, and carbonated beverages act as a continuous lifestyle trigger for acute acid indigestion and GERD.
• A substantial majority of consumers in Mexico rely on OTC self-medication for immediate heartburn relief rather than seeking prescription consultations. The high density of local neighborhood pharmacies (farmacias de simi, independent chemists, and pharmacy chains) makes fast-acting antacids one of the most frequently purchased over-the-counter health categories in the country.
• Traditional liquid and tablet formats are increasingly ceding ground to rapid-dissolve powders and effervescent chewable formulations (e.g., sodium bicarbonate and citric acid combinations). Manufacturers have achieved breakthroughs in taste-masking technologies, neutralizing harsh alkaline profiles with popular regional flavors (such as lime and chamomile) to improve compliance and speed of onset.

Market Outlook

• The rapid growth of retail pharmacy clinics (consultorios adjuntos a farmacias) attached to major Mexican pharmacy chains is streamlining direct access to immediate acid-relief solutions. These hybrid models allow consumers to receive immediate medical triage and buy OTC antacids in a single visit, boosting overall retail volume.
• Product innovation in Mexico is leaning heavily toward dual-action remedies that address both acid neutralization and gas suppression (combining calcium carbonate or aluminum/magnesium hydroxide with simethicone). Additionally, brands are launching plant-infused options incorporating natural digestive soothing agents (such as aloe vera or chamomile) to capture health-conscious demographics.
• The market is driven by major multinational pharmaceutical companies like Genomma Lab (makers of Alka-Seltzer regionally / local brands), Reckitt Benckiser, Sanofi, Bayer México, and Haleon, with regulatory governance and industry advocacy led by COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) and AFAMELA (Asociación de Fabricantes de Medicamentos de Libre Acceso).

Market Dynamics

Driver: Dietary triggers & prevalence of uninvestigated heartburn
High consumption of spicy foods, fried cuisine, citrus, and carbonated beverages acts as a continuous lifestyle driver for acute acid indigestion across Mexico. With 19.6% of Mexican adults experiencing uninvestigated heartburn, the constant presence of dietary triggers fuels steady, year-round demand for immediate over-the-counter (OTC) acid neutralization.
Challenge: Heavy reliance on unsupervised self-medication
Over 80% of Mexican consumers resort to OTC self-medication for acute gastrointestinal discomfort rather than formal medical consultation. Prolonged, unmonitored use of mineral-based antacids raises significant health risks such as systemic alkalosis, rebound hyperacidity, and electrolyte imbalances while masking underlying severe conditions like erosive GERD or peptic ulcers.
Trend: Expansion of effervescent & regional flavored formulations
Fast-dissolving effervescent powders and chewable formats are outperforming traditional liquid suspensions in popular appeal. To boost compliance, pharmaceutical manufacturers are employing advanced taste-masking technologies and introducing culturally tailored flavors such as lime, chamomile, and herbal infusions to offset harsh alkaline profiles.

Procurement and Industry Impact

• Solid oral formulations lead production volume, with traditional tablets accounting for 41.6% of revenue. However, growing consumer demand for fast-acting effervescent sachet packets and chewable soft-gels requires raw material buyers to secure consistent supplies of specialized excipients, moisture-barrier foils, and effervescent disintegrants.
• Calcium carbonate, sodium bicarbonate, and magnesium hydroxide remain the core active pharmaceutical ingredients (APIs) for Mexican production lines, with calcium carbonate capturing 35.5% of active ingredient demand. Because domestic chemical synthesis is limited, procurement managers depend heavily on medical-grade API imports subject to foreign exchange volatility and international shipping tariffs.
• Retail pharmacies control 53.6% of distribution, driven in large part by the ubiquity of pharmacy-adjacent clinics (consultorios adjuntos a farmacias). To maintain high volume across these national chains and independent chemist networks, manufacturers allocate significant trade spend and supply allowances, directly impacting wholesale margins.

Segment Analysis

Mexico Antacids Market By Drug Class
• Acid neutralizers remain a core component of gastrointestinal self-care in Mexico because they provide direct neutralization of gastric acid and are suited to episodic heartburn, acid indigestion and sour-stomach symptoms. Calcium carbonate, magnesium hydroxide, aluminum hydroxide and related mineral-based ingredients are important approaches. The category benefits from strong consumer familiarity, particularly for products intended for rapid symptom relief. Mexico's medicines are regulated through COFEPRIS, which maintains a database of authorized medicines and sanitary registrations.
• Proton Pump Inhibitors (PPIs) occupy a more disease-management-oriented position because they reduce gastric acid secretion rather than neutralizing acid already present. Mexican clinical practice makes PPIs particularly relevant to GERD, gastritis and peptic-ulcer-related treatment. A multicenter Mexican survey involving 1,851 patients treated with PPIs and 215 physicians across 36 cities found gastritis, GER and peptic ulcer among the principal reported indications, accounting for 48.8%, 38.5% and 6.2%, respectively.
• H2 antagonists provide an alternative acid-suppression mechanism by blocking histamine H2 receptors in gastric acid-producing cells. Their positioning can appeal to consumers seeking acid reduction without moving directly toward longer-term PPI therapy. In Mexico, the segment is influenced by the distinction between medicines authorized for consumer access and those requiring greater healthcare-professional involvement, with COFEPRIS responsible for medicine authorization and surveillance.
• Pro-motility agents represent a specialized part of the broader gastrointestinal-treatment landscape rather than conventional acid-neutralizing therapy. They are more relevant where reflux or upper-GI symptoms coexist with altered gastrointestinal motility or delayed gastric emptying. Mexican clinical literature also identifies prokinetics among treatments used for gastrointestinal symptoms in patients receiving PPIs, reinforcing their role as complementary rather than direct antacid therapies.
• Combination formulations are particularly useful when Mexican consumers experience overlapping symptoms such as heartburn, acid indigestion, gas or abdominal discomfort. Combining acid-neutralizing ingredients with anti-gas or reflux-barrier components can create a broader symptom-relief proposition. Combination products also allow manufacturers to differentiate mature antacid offerings through multi-symptom positioning and convenient dosing.

Mexico Antacids Market By Dosage Form • Tablets and chewables are well suited to portable, on-demand treatment because consumers can carry individual doses and use them without measuring a liquid. Chewable formats can be particularly attractive for episodic heartburn after meals, while tablet formats provide standardized unit dosing. Mexico's regulatory system requires medicines intended to treat or relieve disease or symptoms to fall within the regulated health-product framework and obtain appropriate sanitary authorization.
• Liquid suspensions provide an important alternative for consumers who have difficulty swallowing solid dosage forms. They can also accommodate combinations of antacid ingredients and provide a familiar administration format for family-oriented gastrointestinal products. From a product-development perspective, suspension stability, uniform distribution of active ingredients, dosing accuracy and flavour are important differentiation factors.
• Powders offer flexibility in administration and can be designed to disperse rapidly after mixing. They can appeal to consumers who prefer alternatives to conventional tablets, although the requirement to prepare the product can reduce convenience compared with ready-to-use liquids or chewables. Packaging must therefore protect the formulation against humidity and maintain accurate dosing instructions.
• Gels and syrups emphasize smooth swallowing and can provide a distinct sensory experience compared with solid formulations. Liquid and syrup-like presentations can also facilitate multi-ingredient formulations. In Mexico, oral pharmaceutical forms such as suspensions, syrups, powders and tablets are recognized within the country's broader pharmaceutical regulatory environment. COFEPRIS states that pharmaceutical products require sanitary authorization when they are intended to treat, cure, prevent or relieve disease or symptoms.
• Gummies and other formats represent a more consumer-oriented direction for gastrointestinal self-care. Gummies can improve portability and make administration more approachable, but they present formulation challenges because conventional antacid actives can require relatively substantial quantities. Other formats such as effervescent or rapidly dispersible products can differentiate themselves through administration experience and perceived speed of action.

Mexico Antacids Market By Indication • Gastroesophageal Reflux Disease (GERD) is an important indication for Mexico's broader acid-control market because recurring reflux symptoms can lead consumers toward antacids, H2 antagonists or PPIs depending on severity and frequency. A Global Burden of Disease analysis estimated approximately 16.68 million people with GERD in Mexico in 2017, providing an indication of the substantial population affected by the condition.
• Heartburn is a major driver of gastrointestinal self-care because it is a recognizable symptom that consumers may attempt to manage before seeking medical consultation. A population-based Mexican study involving 500 people found uninvestigated heartburn in 19.6% of participants. Another Mexican study found that GER was confirmed in 62.5% of patients reporting heartburn, highlighting the clinical overlap between a consumer-recognized symptom and underlying reflux disease.
• Peptic ulcer represents a more clinically managed indication than occasional heartburn. Acid suppression can form part of ulcer treatment, particularly when ulcers are associated with H. pylori infection or other recognized causes. Mexican PPI-treatment data demonstrate this clinical connection: peptic ulcer accounted for 6.2% of reported PPI indications in the multicenter survey of 1,851 patients.
• Others include acid indigestion, dyspepsia, sour stomach, abdominal discomfort and overlapping upper-gastrointestinal symptoms. This segment is important because Mexican consumers may initially describe their condition through symptoms rather than a formal diagnosis. The Mexican population study found that gastrointestinal disorders were common and that people with functional gastrointestinal disorders reported substantially greater medication use and healthcare utilization than controls.

Mexico Antacids Market By Distribution Channel • Retail pharmacies are particularly important because Mexico has a large pharmacy-based medicine purchasing culture, with consumers able to access a broad range of gastrointestinal products. Pharmacies also provide an opportunity for pharmacist interaction when consumers are uncertain whether symptoms should be managed with an antacid, acid suppressant or another gastrointestinal product. COFEPRIS maintains national databases covering pharmacy sanitary licences and authorized medicines, reinforcing the formal role of regulated pharmacy channels.
• Hospital pharmacies serve a more clinically directed segment, particularly patients with diagnosed GERD, peptic ulcers, gastritis and other gastrointestinal disorders. Demand through this channel is influenced more by physician diagnosis, hospital formularies and treatment protocols than by spontaneous consumer purchasing. It is therefore more closely connected with prescription and medically supervised acid-control therapies.
• Online pharmacies / E-commerce provide an increasingly convenient route for consumers seeking repeat purchases, product comparisons and home delivery. However, regulatory authenticity is especially important in Mexico because COFEPRIS warns against purchasing medicines through informal channels such as street markets and unauthorized vendors. COFEPRIS specifically maintains medicine-registration and pharmacy-licensing databases that can help distinguish authorized products and establishments from unregulated sources.


Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Antacids Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Drug Class
• Acid Neutralizers
• Proton Pump Inhibitors (PPIs)
• H2 Antagonists
• Pro-Motility Agents
• Combination Formulations

By Dosage Form
• Tablets & Chewables
• Liquid Suspensions
• Powders
• Gels & Syrups
• Gummies & Other

By Indication
• Gastroesophageal Reflux Disease
• Heartburn
• Peptic Ulcer
• Others

By Distribution Channel
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies / E-Commerce